These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32281039)

  • 1. Antagonism of cysteinyl leukotrienes and their receptors as a neuroinflammatory target in Alzheimer's disease.
    Singh RK
    Neurol Sci; 2020 Aug; 41(8):2081-2093. PubMed ID: 32281039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Trends in the Management of Alzheimer's Disease: Current Therapeutic Options and Drug Repurposing Approaches.
    Singh RK
    Curr Neuropharmacol; 2020; 18(9):868-882. PubMed ID: 31989900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel therapeutic potential of cysteinyl leukotrienes and their receptors modulation in the neurological complications associated with Alzheimer's disease.
    Rahman SO; Singh RK; Hussain S; Akhtar M; Najmi AK
    Eur J Pharmacol; 2019 Jan; 842():208-220. PubMed ID: 30389631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of neuroinflammation by cysteinyl leukotriene 1 and 2 receptors: implications for cerebral ischemia and neurodegenerative diseases.
    Wang Y; Yang Y; Zhang S; Li C; Zhang L
    Neurobiol Aging; 2020 Mar; 87():1-10. PubMed ID: 31986345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases.
    Sasaki N; Fukatsu R; Tsuzuki K; Hayashi Y; Yoshida T; Fujii N; Koike T; Wakayama I; Yanagihara R; Garruto R; Amano N; Makita Z
    Am J Pathol; 1998 Oct; 153(4):1149-55. PubMed ID: 9777946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype.
    Berg L; McKeel DW; Miller JP; Storandt M; Rubin EH; Morris JC; Baty J; Coats M; Norton J; Goate AM; Price JL; Gearing M; Mirra SS; Saunders AM
    Arch Neurol; 1998 Mar; 55(3):326-35. PubMed ID: 9520006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential therapeutic targets for Alzheimer's disease.
    Chen F; Ghosh A; Lin J; Zhang C; Pan Y; Thakur A; Singh K; Hong H; Tang S
    Brain Behav Immun; 2020 Aug; 88():844-855. PubMed ID: 32222525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional characterisation of receptors for cysteinyl leukotrienes in smooth muscle.
    Jonsson EW
    Acta Physiol Scand Suppl; 1998 Mar; 641():1-55. PubMed ID: 9597121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenylpropanoids and Alzheimer's disease: A potential therapeutic platform.
    Kolaj I; Imindu Liyanage S; Weaver DF
    Neurochem Int; 2018 Nov; 120():99-111. PubMed ID: 30098379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroinflammation as a Potential Therapeutic Target in Alzheimer's Disease.
    Liu P; Wang Y; Sun Y; Peng G
    Clin Interv Aging; 2022; 17():665-674. PubMed ID: 35520949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Delivery of Montelukast for the Treatment of Alzheimer's Disease.
    Datusalia AK; Singh G; Yadav N; Gaun S; Manik M; Singh RK
    CNS Neurol Disord Drug Targets; 2022; 21(10):913-925. PubMed ID: 34477536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review on Alzheimer's disease pathophysiology and its management: an update.
    Kumar A; Singh A; Ekavali
    Pharmacol Rep; 2015 Apr; 67(2):195-203. PubMed ID: 25712639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease.
    Landén M; Thorsell A; Wallin A; Blennow K
    J Neurol Neurosurg Psychiatry; 1996 Oct; 61(4):352-6. PubMed ID: 8890772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease plaques and tangles: cemeteries of a pyrrhic victory of the immune defence network against herpes simplex infection at the expense of complement and inflammation-mediated neuronal destruction.
    Carter CJ
    Neurochem Int; 2011 Feb; 58(3):301-20. PubMed ID: 21167244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathogenesis of Alzheimer's disease: molecular and cellular mechanisms].
    Govaerts L; Schoenen J; Bouhy D
    Rev Med Liege; 2007 Apr; 62(4):209-16. PubMed ID: 17566391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Etiology and pathogenesis of Alzheimer dementia].
    Kratzsch T; Peters J; Frölich L
    Wien Med Wochenschr; 2002; 152(3-4):72-6. PubMed ID: 11925775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research Progress of Targeting Neuro-Immune Inflammation in the Treatment of Alzheimer's Disease.
    Chen H; Deng C; Meng Z; Meng S
    Front Biosci (Landmark Ed); 2022 Nov; 27(11):312. PubMed ID: 36472107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroinflammation in Alzheimer's Disease: Microglia, Molecular Participants and Therapeutic Choices.
    Wang H; Shen Y; Chuang H; Chiu C; Ye Y; Zhao L
    Curr Alzheimer Res; 2019; 16(7):659-674. PubMed ID: 31580243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring Potential of Alkaloidal Phytochemicals Targeting Neuroinflammatory Signaling of Alzheimer's Disease.
    Uddin MS; Kabir MT; Al Mamun A; Behl T; Mansouri RA; Aloqbi AA; Perveen A; Hafeez A; Ashraf GM
    Curr Pharm Des; 2021; 27(3):357-366. PubMed ID: 32473620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The usefulness and challenges of transgenic mouse models in the study of Alzheimer's disease.
    Wilcock DM
    CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):386-94. PubMed ID: 20522016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.